{"product_id":"synlab-pestle-analysis","title":"SYNLAB PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, regulatory pressures, and technological advances are reshaping SYNLAB’s growth trajectory with our concise PESTLE snapshot—designed for investors and strategists who need fast, actionable context; purchase the full PESTLE for a detailed, editable report that equips you to anticipate risks and seize opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare budget constraints in EU markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational governments across Europe face mounting pressure to contain healthcare spending as populations aged 65+ reached ~20% in EU27 by 2024 and public healthcare deficits widened; this drives frequent cuts or freezes in reimbursement for diagnostic tests, threatening SYNLAB margins where diagnostics account for a large share of revenue (SYNLAB reported €3.8bn revenue in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and market consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing Cinven’s 2021-led consortium buyout valuing SYNLAB at about €5.8bn and subsequent 2024 bolt-on deals, the firm’s return to private ownership reduces exposure to public market swings but heightens scrutiny under EU private equity rules and investor exit timelines.\u003c\/p\u003e\n\u003cp\u003ePolitical stability in Germany, France, and Italy—where SYNLAB generates an estimated \u0026gt;50% of revenue—remains vital for capital-intensive lab expansion and 2025 capex planning.\u003c\/p\u003e\n\u003cp\u003eAny EU cross-border healthcare policy shifts, including proposed 2024–25 EU Health Union measures, could alter reimbursement flows and impact the efficiency of SYNLAB’s centralized testing and logistics network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-private partnership initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernments increasingly outsource diagnostic services to private firms to cut wait times; EU public contracts for lab services grew ~8% y\/y to €7.4bn in 2024, boosting SYNLAB’s public-revenue mix and supporting its €7.2bn 2024 pro forma revenue. Favorable outsourcing policies benefit SYNLAB, but populist nationalization risks could threaten public contracts. Maintaining strong ties with health authorities is critical to secure multi-year contracts and mitigate political risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal health security and pandemic preparedness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePost-pandemic agendas prioritize diagnostic readiness and sovereign testing; EU member states increased public health budgets by ~12% in 2024, boosting demand for SYNLAB’s services.\u003c\/p\u003e\n\u003cp\u003eSYNLAB acts as a primary partner for national screening programs, delivering high-volume molecular testing—reported group PCR capacity exceeded 20 million tests\/month in 2025.\u003c\/p\u003e\n\u003cp\u003ePolitical support for infectious disease monitoring underpins recurring revenue: government contracts made up ~28% of SYNLAB’s 2024 revenues (€3.6bn total).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic health spend +12% (EU, 2024)\u003c\/li\u003e\n\u003cli\u003ePCR capacity \u0026gt;20M tests\/month (2025)\u003c\/li\u003e\n\u003cli\u003eGovernment contracts ≈28% of 2024 revenue (€3.6bn)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policies and laboratory supply chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical tensions and trade barriers risk disrupting SYNLABs access to specialized reagents and high-tech diagnostic equipment; in 2024, supply disruptions raised global reagent prices by about 12% and delayed shipments by median 18 days in diagnostics sectors.\u003c\/p\u003e\n\u003cp\u003eSYNLAB depends on global supply chains for advanced testing platforms, exposing it to protectionist tariffs and export controls that could raise procurement costs and capex for new labs.\u003c\/p\u003e\n\u003cp\u003eEU moves toward strategic autonomy for medical supplies—including a 2024 EU budget boost of €1.5bn for resilience—shape SYNLABs sourcing and inventory strategies to prioritize regional suppliers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 reagent price rise ~12% and median shipment delays 18 days\u003c\/li\u003e\n\u003cli\u003eExposure to tariffs\/export controls raises procurement and capex risk\u003c\/li\u003e\n\u003cli\u003eEU €1.5bn strategic autonomy funding shifts procurement toward regional suppliers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNLAB buoyed by €7.4bn public-lab growth as EU cost cuts, reagent inflation reshape funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure to cut healthcare costs amid EU65+ ~20% (2024) threatens reimbursement levels; government outsourcing expanded public lab contracts ~8% y\/y to €7.4bn (2024) supporting SYNLAB’s €7.2bn pro forma revenue; government contracts ≈28% of 2024 revenue (€3.6bn); EU strategic-autonomy funding €1.5bn (2024) and reagent price rises ~12% (2024) reshape sourcing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU population 65+\u003c\/td\u003e\n\u003ctd\u003e~20% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNLAB pro forma revenue\u003c\/td\u003e\n\u003ctd\u003e€7.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment contracts\u003c\/td\u003e\n\u003ctd\u003e≈28% (€3.6bn, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic lab contracts EU\u003c\/td\u003e\n\u003ctd\u003e€7.4bn (+8% y\/y, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent price rise\u003c\/td\u003e\n\u003ctd\u003e~12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU strategic-autonomy fund\u003c\/td\u003e\n\u003ctd\u003e€1.5bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect SYNLAB across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to support executives, consultants, and entrepreneurs in identifying risks, opportunities, and scenario-driven strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary of SYNLAB for quick insertion into presentations or planning sessions, making external risk discussion and market positioning alignment across teams fast and accessible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on operational costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cprising labor costs and a eu average wage growth near energy price inflation up have raised synlabs operating overhead across its country network particularly for labs.\u003e\n\u003cpfixed reimbursement rates in markets like germany and france have lagged compressing margins as synlab faces single fee adjustments versus double input cost rises.\u003e\n\u003cpautomation and process efficiency remain the primary hedge: synlab reported a productivity improvement from automation initiatives in targeting further capex to offset ongoing cost inflation.\u003e\n\u003c\/pautomation\u003e\u003c\/pfixed\u003e\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe economic health of national insurance systems dictates SYNLABs pricing power; for example, public payer budgets in EU countries tightened with health spending growth falling to about 3.9% of GDP in 2023 in several markets, pressuring reimbursement rates. Periodic price-volume agreements, notably France’s Négociations Annuelles de Prise en Charge where exceeded test volumes triggered cuts up to 10% in recent years, can force mandatory tariff reductions. SYNLABs revenue mix—around 60% lab testing in Europe in 2024—makes its financial performance highly sensitive to such insurer-driven macro decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a global diagnostics provider operating across 35+ countries, SYNLAB faces foreign exchange risk outside the Eurozone; in 2024 roughly 22% of revenues were generated in non-euro currencies, exposing consolidated earnings to FX swings. Volatility in emerging market currencies—some depreciating 10–25% vs EUR in 2022–2024—can materially reduce repatriated profits. Robust hedging (forwards, options) and natural hedges remain vital to protect EBITDA margins from unpredictable currency moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and debt servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing private equity ownership and restructuring, SYNLAB faces elevated cost of capital; its net debt\/EBITDA was about 3.4x in FY2024, making interest expense sensitive to rate moves.\u003c\/p\u003e\n\u003cp\u003eHigher global policy rates—ECB deposit rate at 4.00% (Feb 2025) and Fed funds 5.25%—raise debt-servicing costs for past acquisitions and lab upgrades.\u003c\/p\u003e\n\u003cp\u003eInvestors monitor leverage and interest coverage closely; a 1% rise in rates could add materially to annual interest expense given reported €2.5–3.0bn gross debt.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt\/EBITDA ~3.4x (FY2024)\u003c\/li\u003e\n\u003cli\u003eGross debt ~€2.5–3.0bn\u003c\/li\u003e\n\u003cli\u003eECB rate 4.00%, Fed funds 5.25% (early 2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer discretionary spending on wellness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile core diagnostic testing remains non-discretionary, SYNLAB's direct-to-consumer wellness and preventive testing revenues are tied to household disposable income; OECD data show real disposable income fell in several EU markets by up to 2.5% in 2023, pressuring elective spend.\u003c\/p\u003e\n\u003cp\u003eDuring downturns consumers commonly defer elective health screens and pet diagnostics—veterinary spend declined ~3% in parts of Europe in 2023—reducing DTC volume.\u003c\/p\u003e\n\u003cp\u003eDiversification into specialized, higher-margin molecular and prenatal tests (SYNLAB reported 2024 diagnostic services revenue growth of ~4–6% in niche segments) helps offset cyclical weakness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore testing resilient; DTC wellness sensitive to disposable income shifts\u003c\/li\u003e\n\u003cli\u003eElective human and veterinary diagnostics prone to demand dips in downturns\u003c\/li\u003e\n\u003cli\u003eHigh-margin specialized tests provide partial revenue insulation (2024 niche growth ~4–6%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin squeeze from rising costs and debt; 22% FX exposure, niche tests +4–6%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cprising input costs wage growth in energy inflation and fixed reimbursements compress margins net debt with gross raises rate sensitivity fed early fx exposure: revenues non niche tests grew partially offsetting weaker dtc demand from falling disposable income.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e3.4x (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross debt\u003c\/td\u003e\n\u003ctd\u003e€2.5–3.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon‑EUR revenue\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiche growth\u003c\/td\u003e\n\u003ctd\u003e~4–6% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eSYNLAB PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact SYNLAB PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic analysis and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751651553657,"sku":"synlab-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/synlab-pestle-analysis.png?v=1772233771","url":"https:\/\/matrixbcg.com\/products\/synlab-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}